Logout Login Cart iconShop Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "Where To Buy Sedatives"

Looking for quality documents?
external link icon
Repligen Acquires Atoll GmbH
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH (“Atoll”) of Weingarten, Germany, an innovator and manufacturer of MediaScout® pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen’s pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company’s existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats.   Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares 1  of Repligen common stock, for total upfront consideration of approximately
external link icon
Repligen Receives Milestone Payment From Pfizer
WALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million milestone payment from Pfizer, Inc. under the terms of the companies' exclusive worldwide licensing agreement (the "Agreement") for the development of compounds to potentially treat spinal muscular atrophy (SMA), a neuromuscular disease that typically presents in children under age two. Since announcing the Agreement in January 2013, Repligen has received $7 million in upfront and milestone payments. Repligen remains eligible to receive up to $63 million in additional performance-based milestone payments, as well as royalties on any future sales of compounds developed under the Agreement. 2014 Revenue Repligen also today reported preliminary, unaudited total revenue of $63-$63.5 million for the fiscal year ended December 31, 2014. This total revenue figure is comprised of approximately $3 million in revenue from out-licensed therapeutic
external link icon
Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington’s Disease Model
publications icon
Reducing Clinical-Phase Manufacturing Costs: Collaborating for Savings without Compromising Quality or Performance Publication
In downstream purification of monoclonal antibodies (MAbs), the single greatest contributor to manufacturing costs is the expensive capture step typically based on protein A affinity chromatography. Almost since its introduction to bioprocessing, efforts have been made to reduce the cost of this step.
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 1.5 million shares of its common stock at a public offering price of $181 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 225,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $271.5 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about December 10, 2020 subject to customary closing conditions.

Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 410,156 shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $175 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about May 3, 2019 subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott is acting as lead manager for the offering. These securities
external link icon
Repligen Corporation Prices Public Offering of Shares of Common Stock
WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the pricing of an underwritten public offering of 2,807,017 shares of its common stock at a public offering price of $42.75 per share. In addition, Repligen Corporation has granted the underwriters a 30-day option to purchase up to an additional 421,052  shares of its common stock at the public offering price, less underwriting discounts and commissions. Repligen expects proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately $120 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on or about July 3, 2017, subject to customary closing conditions.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint book-running managers for the offering. Janney Montgomery Scott LLC is acting as lead co-manager for the offering and
external link icon
Repligen Corporation Names Tony Hunt as Next Chief Executive Officer
WALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. Hunt to be the Company's next Chief Executive Officer. Mr. Hunt, currently Repligen's Chief Operating Officer, will succeed Walter C. Herlihy, Ph.D., who will retire as President and CEO effective May 21, 2015, the date of the Company's Annual Meeting of Stockholders. "Under Walter's leadership, Repligen has been transformed from a therapeutics company that produced bioprocessing products into a focused bioprocessing industry leader, providing high-value consumable products for biological manufacturers and creating substantial value for our stockholders," commented Karen A. Dawes, Chair of the Board of Repligen. "Walter has been a major force in building this outstanding company, and the Board and I, on behalf of the stockholders, thank Walter for his dedication, vision, and leadership." Ms. Dawes continued, "We are delighted to promote
external link icon
Repligen Announces Support of Amended Stockholder Proposal
external link icon
Karen A. Dawes Elected as Repligen Co-chairperson of the Board of Directors